Overexpressed CKAP4 was significantly associated with tumor, nodal, and metastasis stages, as well as Fuhrman grades.
Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.
Although cytogenetic abnormalities that arise during the course of CML are prevalent in later stages of the disease and are associated with a poorer prognosis, as many as 10% to 12% of patients exhibit ACAs at diagnosis.
Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.
It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?
- NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration
- Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma